HNHesham Nada

Hesham Nada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hesham Nada has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gene and tissue expression of CCL13 in vitiligo patients: correlation with disease activity and severity: a case control study

    by Aya Mohamed Abd El-Baset Morad, Moustafa Mohamed Kamel Eyada, Hesham Ahmed Nada, Shymaa Ahmed Maher, Wael Ahmed Maher, Radwa El-Sayed Mahmoud Marie


  • Open Access

    CXCL13 Serum Level as a Potential Biomarker in Vitiligo Patients: Correlation with Disease Activity and Severity

    by Yasmine Ashraf, Nader Ali Ismail, Hanan Omar, Hesham Nada

    Background: Vitiligo is a prevalent autoimmune pigmentary skin disorder, with 0.5 - 2% of the global population prevalence. Human follicular T helper cells, dendritic follicular cells, and mesenchymal lymphoid tissue organizer cells all generate the B-cell chemokine (C-X-C motif) ligand 13 (CXCL13). Chemokine (C-X-C motif) ligand 13 and its receptor CXCR5 have been linked to the etiopathogenesis of various autoimmune and inflammatory diseases in the latest studies. Objectives: This study aimed to assess the serum CXCL13 level in vitiligo patients and its relation to the activity and severity of the disease. Methods: This case-control study involved 21 vitiligo patients and 21 age and gender-matched healthy controls. Full history taking, clinical evaluation, and assessment of the disease activity and severity were performed for all the patients. The CXCL13 serum levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: The serum CXCL13 levels were significantly higher in vitiligo patients than in healthy controls (227.35 ± 125.70 and 130.58 ± 26.52 ng/L, respectively; P = 0.002). There was a significant relationship between CXCL13 and the clinical pattern of activity among patients with vitiligo; however, there was no correlation with disease activity or severity index scores. Conclusions: Although CXCL13 was greater in vitiligo patients than in healthy controls, it was unrelated to the activity or severity of the illness. This finding suggests that CXCL13 might have a role in the immunological pathogenesis of vitiligo.

  • Open Access

    Prevalence of Female Sexual Dysfunction among Psoriatic Females: a Cross Sectional Case Controlled Study

    by Mohamed Elsaie, Noha Hanafy, Sherief Hussein, Ola Abu Zeid, Mohamed Zaky, Ramadan Eldahshan, Hesham Nada, Osama Sayedahmed, Yasmin El Zawahry

    Introduction: Sexual relationships are an integral part of females psychological and physiological wellbeing. Objectives: The study aimed to identify prevalence and impact of Female Sexual Dysfunction (FSD) in women affected with psoriasis. Methods: This cross-sectional study was carried out on 150 married females who were interviewed to answer Female Sexual Function Index (FSFI) questionnaire and were divided into two groups: the first group included 100 female patients complaining of psoriasis (50 suffering from moderate psoriasis and 50 with severe psoriasis). The disease severity was graded according to the Psoriasis Area and Severity Index (PASI) while the second group included 50 age matched women who served as controls. Results: Female sexual dysfunction (FSD) in psoriasis female groups was higher than that in the control group (47%, 24%, P < 0.05). The mean total scores of FSFI ranged from 12.30 to 34.20 and were significantly lower in the severe PASI affected group (22.34 ± 5.35) when compared to moderate PASI group (26.24 ± 2.67) or control group (28.79 ± 2.22). In addition, total scores were significantly lower among moderate PASI affected females when compared to control group. Conclusions: Sexual dysfunction should be routinely investigated in female patients with psoriasis in the case of moderate-severe disease due to its negative impact on quality of life. Further research over the effect of certain interventional programs on FSD should be considered for patients suffering from psoriasis.


  • Open Access

    Comparing the Therapeutic Efficacy of Intradermal Injection of Platelet-Rich Plasma and Topical Application of Hydroquinone 2% in Melasma Treatment

    by Hesham A. Nada, Nader A. Ismail, Shaymaa A. Abd El Hady, Aya F. Mohamed

    Background: Melasma is a condition that causes the skin to get darker over time. There have been several therapies for melasma that have had mixed effects. Objective: To compare two therapeutic modalities for melasma; topical hydroquinone 2 percent and intradermal injection of PRP. Methods: Acase-control study of 60 mixed melasma female patients with Fitzpatrick skin types II, III, and IV was conducted. The patients were then separated into two groups: group (1) was treated with intradermal PRP injections for four sessions every three weeks, while Group (2) was treated with topical hydroquinone 2 percent for nine weeks. The % decrease in baseline MASI score and digital photography were used to evaluate the results. Results: MASI score was calculated at (0, 3, 6, 9 weeks) and after the last session by one month. PRP group and the Hydroquinone group were significantly different regarding the changes in the mean score of MASI score at week 13 of the study (P = 0.002). The mean MASI score was reduced by 54.79% in the PRP group and 24.52% in the hydroquinone group at week 13. Conclusion: Melasma may benefit from the use of platelet-rich plasma as an alternative therapy.

  • Open Access

    Quality of Life among Psoriasis Patients; Correlation with Severity and Response to Psoralen Ultraviolet-A phototherapy

    by Hesham Nada, Sherin Fikry, Wafaa Hagag

    Background: Psoriasis is a chronic inflammatory skin disorder that affects 2-4% of the world’s population, causing psychological, physical, and social impairment. Although the management of psoriasis patients has become increasingly effective, it can only result in a temporary remission of physical symptoms. A challenge to dermatologic care is to achieve a long-lasting remittance of the disease and a substantial improvement in quality of life. Aim: This study aims to assess the quality of life of psoriatic patients and their response to PUVA therapy. Patients and Methods: The study included 36 patients presented with varying degrees of psoriasis. All patients were subjected to full history taking, total skin examination, assessment of psoriasis severity by PASI, and measurement of quality of life (QoL) by QoL inventory (QoLI) both before and 1.5- 2 months after treatment with PUVA. Results:After treatment with PUVA the mean PASI score decreased significantly (P=0.001) from 28.94±11.02 to 22.51±11.66, In addition, the QoLI scores were significantly (P=0.001) elevated from 30.38±19.83 before treatment to 48.58±23.58 after treatment. Conclusion: There was a good effect of PUVA therapy on patients with psoriasis as regards the severity of the disease and quality of life; moreover, the social and psychological aspects should be considered and managed in the management of psoriasis.

  • Open Access

    Serum Level of Survivin in Patients with Alopecia Areata and its Association with Disease Severity and Progression

    by Hesham A. Nada, Samah G. Gad El- Hak, Nashwa R. Hassan, Radwa E. Marie

    Background: Alopecia areata (AA) is an acquired cytotoxic T-cell immune-mediated hair loss disorder. The autoimmune attack triggers apoptosis with rapid progression of hair follicles (HFs) from the anagen to catagen and telogen phases of the hair cycle. Survivin is an inhibitor of apoptosis protein responsible for cell cycle regulation and apoptosis inhibition. Its expression has been determined in proliferating anagen HF cells, whereas its expression prominently decreases during the catagen phase. Aim: This study aimed to evaluate serum survivin level in AA patients and its relationship with AA severity and progression. Subjects and Methods: The study included 38 AA patients and 38 healthy controls. Alopecia areata severity was assessed by the severity of the Alopecia Tool score. Serum survivin level was measured by enzyme-linked immune-sorbent assay. Results: Serum Survivin level was significantly lower in AA patients than in controls (p < /em>= 0.009). Moreover, the level was significantly lower in patients with progressive disease than in those with stable disease (p < /em> < 0.001) and duration (p=0.003). Conclusion: Survivin serum level was decreased in AA patients. Thus, survivin could have a potential role in AA immune pathogenesis and its serum level might be a predictor for AA severity and progression.

  • Open Access

    Tissue Expression of Nuclear Factor Kappa Beta in Psoriasis Vulgaris Before and After Psoralen Ultraviolet-A Therapy: A Prospective Study

    by Hesham Nada, Sherine El-Saman, Abeer Mohamed

    Background:Nuclear factor kappa beta is an inducible nuclear transcription factor regulating a range of cellular processes. Nuclear factor kappa beta is considered to impact many cellular phenomena such as inflammation, immune responses, proliferation, differentiation, apoptosis, and tumor progression, therefore considered to have a major role in many inflammatory skin diseases including the pathogenesis of psoriasis. Aim: This study aims to investigate nuclear factor kappa beta tissue expression in patients with psoriasis vulgaris before and after Psoralen Ultraviolet A therapy. Subjects and Methods: Thirty patients with generalized chronic plaque psoriasis were assigned as a test group (Group I) and 10 age-and sex-matched healthy individuals assigned as a control group (Group II) were enrolled in this study. Skin biopsy specimens were subjected to histopathological study and immunohistochemical determination ofnuclear factor kappa beta before and after 30 sessions of Psoralen Ultraviolet A therapy. Results: This study revealed highly constitutive tissue expression ofnuclear factor kappa beta in all psoriatic lesions with variable degrees in comparison with control specimens (p < 0.001). Also, there was a significant decrease in nuclear factor kappa beta expressionin psoriatic skin after Psoralen Ultraviolet A therapy (p < 0.001).Conclusion:Psoralen Ultraviolet A therapy among psoriatic patients demonstrated a decrease in PASI score, epidermal thickness; mononuclear cellular infiltration, as well as nucleocytoplasmic positivity (active nuclear factor kappa beta form) expression, accordingly selective blockade of nuclear factor kappa beta could be an effective treatment for psoriasis.


  • Open Access

    Tissue Expression of Protease Activated Receptor 2 in Patients with Pruritus in Chronic Kidney Disease

    by Hesham A. Nada, Gamal A. Hafez, Mohammed M. Keshawy, Eman G. Abdelrahman

    Background: Uremic pruritus has been defined as itching that is directly related to kidney disease, without any other comorbid condition that causes itching. The exact pathogenesis of uremic pruritus remains unclear but, protease-activated receptor 2 (PAR2) is claimed to have a pivotal role in the pathogenesis of uremic pruritus. Aim: Evaluation of PAR2 activity in the epidermis of patients with chronic kidney disease (CKD) complaining of pruritus. Subjects and Methods: Case-control study on 48 individuals (24 CKD patients complaining from pruritus and 24 matched healthy controls). Skin biopsy specimens from all participants were taken from a similar area of the back of forearms then immunohistochemical analysis for PAR2 activity in the epidermis was performed. Results: Data revealed that epidermal PAR-2 expression was significantly higher in CKD patients compared to healthy controls. PAR2 staining intensity in skin biopsies was moderate in 9 (37.5%) patients and strong in 15 (62.5%) patients in the cases group. On the other hand, PAR2 staining was moderate in all 24 (100%) cases in the control group which was statistically significant.Conclusion: Epidermal PAR-2 expression is increased in CKD patients with pruritus.

  • Psoriasis: is it a risk factor for cardiovascular diseases?

    by Hesham Nada, Attef Elakhrass, Neven Ahmad, Mohamed Refaat

    Psoriasis, newly considered as a systemic inflammatory condition, has a high prevalence of cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction. Measurement of carotid...


  • Association of ICAM-1 gene variant rs5498 (1462A>G) with non-obstructive azoospermia

    by Nervana Bayoumy, Mohamed El-Shabrawi, Hesham Nada

    The blood testicular barrier (BTB) is a barrier protecting the testes from damage. It also plays an important role in spermatogenesis. The intracellular adhesion molecule-1 (ICAM-1) is a member of the immunoglobulin cell adhesion molecule family and is a constituent component of the BTB. This study was carried out to investigate the association between the single nucleotide polymorphism (SNP) rs5498 in the ICAM-1 gene and non-obstructive azoospermia. A total of 100 male patients with non-obstructive azoospermia and 100 fertile males (healthy control) were included in this study. Genotyping of ICAM-1 gene rs5498 was performed using polymerase chain reaction-restriction enzyme fragment length polymorphism (PCR-RFLP). Both AG and GG genotypes were significantly more prevalent among the infertile men compared to the control group (p < 0.001). The odds ratio (OR) for the polymorphic allele (G) was 2.4 with 95% confidence interval from 1.38 to 3.19 (p < 0.001). The study shows that ICAM-1 rs5498 (1462A>G) SNP is positively associated with an increased risk for obstructive azoospermia, with the genotype AG heterozygotes showing a significantly higher frequency among infertile men.